GCM
INZY

Graham Capital Management’s Inozyme Pharma INZY Stock Holding History

Graham Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,044
Closed -$33.4K – 1392
2024
Q4 		$33.4K Buy
+12,044
New +$45.8K ﹤0.01% 1194

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Graham Capital Management's INZY Position: Q1 2025 in Review

Graham Capital Management sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 12,044 shares — an estimated $33.4K sold.

Graham Capital Management first reported a position in INZY in Q4 2024 and held it in 1 quarter. The position peaked at $33.4K in Q4 2024. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • Graham Capital Management reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • Graham Capital Management sold 12,044 Inozyme Pharma shares in Q1 2025, an estimated $33.4K.
  • Graham Capital Management first reported a position in Inozyme Pharma in Q4 2024 and held it in 1 quarter.
  • Graham Capital Management's Inozyme Pharma position peaked at $33.4K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.